The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000598381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/04/2026
Date registered
Help: Date registered
13/05/2026
Date last updated
Help: Date last updated
14/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Buprenorphine vs tapentadol for pain management post haemorrhoidectomy: an open-label randomised clinical trial (BOLT)
Scientific title
Buprenorphine vs tapentadol for pain management post haemorrhoidectomy: an open-label randomised clinical trial (BOLT)
Additional trial identifiers [1] 316940 0
Nil known
Universal Trial Number (UTN)
Trial acronym
BOLT
Related trial records

Health condition
Health condition(s) studied:
Acute pain 341440 0
Condition category
Condition code
Anaesthesiology 337502 337502 0 0
Pain management
Surgery 337503 337503 0 0
Other surgery

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This will be an open-label randomised controlled study.

The intervention arm will be buprenorphine sublingual tablets, plus usual care post-haemorrhoidectomy once patient is tolerating oral tablets.

Dosage and duration will be guided by the product information and adjusted according to individual pain response and clinical judgement. Maximum dose is 1.6mg in 24 hours. Participants will be provided study medications on discharge, receiving a supply of buprenorphine tablets of no more than 20 tablets. The prescribing of buprenorphine will be guided by the treating surgeon, anaesthetist, and pain specialist, with suggested dosing guides provided by the study team from evidence-based resources.

During admission, nursing staff will administer medications for patients. Usual care will be determined by each individual hospital's processes, but may include regular paracetamol and non-steroidal anti-inflammatory medications, and osmotic laxatives and salt baths when required.

As the dosing is on an 'as needed' basis, participants may or may not use the medication in-hospital. Strategies to monitor adherence to the intervention during admission include review of the medication charts and patient notes. Following discharge, the study team will rely on patient-self reports daily to monitor adherence.

Final data collection will be via telephone 3-months after the surgery. The research team will ask about opioid use to assess for persistent use, opioid-related adverse events, nonopioid analgesic use, and benzodiazepine use.
Intervention code [1] 333722 0
Treatment: Drugs
Description of the comparator or control
The comparator arm will be tapentadol immediate-release tablets, plus usual care post-haemorrhoidectomy once patient is tolerating oral tablets.

Dosage and duration will be guided by the product information and adjusted according to individual pain response and clinical judgement. Maximum dose is 600mg in 24 hours. Participants will be provided study medications on discharge, receiving a supply of tapentadol tablets of no more than 20 tablets. The prescribing of tapentadol will be guided by the treating surgeon, anaesthetist, and pain specialist, with suggested dosing guides provided by the study team from evidence-based resources.

During admission, nursing staff will administer medications for patients. Usual care will be determined by each individual hospital's processes, but may include regular paracetamol and non-steroidal anti-inflammatory medications, and osmotic laxatives and salt baths when required.

As the dosing is on an 'as needed' basis, participants may or may not use the medication in-hospital. Strategies to monitor adherence to the intervention during admission include review of the medication charts and patient notes. Following discharge, the study team will rely on patient-self reports daily to monitor adherence.

Final data collection will be via telephone 3-months after the surgery. The research team will ask about opioid use to assess for persistent use, opioid-related adverse events, nonopioid analgesic use, and benzodiazepine use.
Control group
Active

Outcomes
Primary outcome [1] 345009 0
Pain after a bowel motion
Timepoint [1] 345009 0
Measured for the first 7 post-operative days, reported as area under the curve (AUC)
Primary outcome [2] 345011 0
Recruitment rate of eligible patients per month
Timepoint [2] 345011 0
At trial conclusion
Primary outcome [3] 345012 0
Retention rate of eligible patients per month
Timepoint [3] 345012 0
At trial conclusion
Secondary outcome [1] 460103 0
Constipation
Timepoint [1] 460103 0
Once daily, days 1-7 post-operative
Secondary outcome [2] 460105 0
Pain intensity
Timepoint [2] 460105 0
Once daily, days 1-7 postoperative, at rest
Secondary outcome [3] 460109 0
Opioid-related adverse effects
Timepoint [3] 460109 0
Once daily, days 1-7 postoperative and 3 months after surgery
Secondary outcome [4] 460117 0
Persistent Opioid Use
Timepoint [4] 460117 0
3 months after surgery
Secondary outcome [5] 460120 0
Non-opioid analgesic use
Timepoint [5] 460120 0
Baseline, once daily on days 1-7 postoperative, 3-months postoperative
Secondary outcome [6] 460122 0
Benzodiazepene use
Timepoint [6] 460122 0
Baseline, once daily on days 1-7 postoperative, 3-months postoperative
Secondary outcome [7] 460124 0
Opioid use
Timepoint [7] 460124 0
Baseline, once daily on days 1-7 postoperative, 3-months postoperative
Secondary outcome [8] 460125 0
Length of hospital stay
Timepoint [8] 460125 0
Following discharge
Secondary outcome [9] 460126 0
Hospital readmission rate
Timepoint [9] 460126 0
3 months following surgery
Secondary outcome [10] 460127 0
Surgical complications (for example surgical site infections, nerve injury, chest infections)
Timepoint [10] 460127 0
Once daily on days 1-7 postoperative, 3-months postoperative

Eligibility
Key inclusion criteria
Aged equal to or greater than 18 years, elective haemorrhoidectomy, postoperative opioid requirement (clinician judgement), English proficient; telephone/internet access.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Repeat surgery in the last 6 months (i.e., has had a haemorrhoidectomy in the last 6 months), cognitive impairment, chronic opioid use (i.e. daily use for the last 3 months or more), cancer/palliative care, substance disorder, contraindications to study drugs

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation will be conducted using a centralised randomisation service to ensure allocation concealment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised on admission in a 1:1 ratio in permuted blocks of 2 and 4 to: (1) buprenorphine plus usual care post-surgery and on discharge if required; or (2) tapentadol plus usual care post-surgery and on discharge if required. The method of generating the allocation sequence is computer generated random numbers. The randomisation will be stratified by hospital site.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Sample size was calculated for the primary outcome, pain during bowel motion at the first bowel movement, using a two-sided comparison between groups. Based on an expected between-group difference of 1.5 points on the NRS, an SD of 2, 80% power, alpha 0.05, and 20% attrition, the required sample size is 74 participants in total (37 per arm). This sample size is therefore sufficient for the primary superiority hypothesis. This was based off existing literature on postoperative haemorrhoidectomy pain

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321534 0
Hospital
Name [1] 321534 0
South Eastern Sydney Local Health District RES-ON Research Funding Program
Country [1] 321534 0
Australia
Funding source category [2] 321578 0
Hospital
Name [2] 321578 0
Prince of Wales Hospital staff in-kind support
Country [2] 321578 0
Australia
Primary sponsor type
Hospital
Name
Prince of Wales Hospital
Address
Country
Australia
Secondary sponsor category [1] 324375 0
None
Name [1] 324375 0
Address [1] 324375 0
Country [1] 324375 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320069 0
South Eastern Sydney Local Health District HREC
Ethics committee address [1] 320069 0
Ethics committee country [1] 320069 0
Australia
Date submitted for ethics approval [1] 320069 0
20/01/2026
Approval date [1] 320069 0
08/04/2026
Ethics approval number [1] 320069 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149326 0
A/Prof Jonathan Penm
Address 149326 0
N371, Pharmacy and Bank Building A15 The University of Sydney, NSW, 2006
Country 149326 0
Australia
Phone 149326 0
+61 286275806
Fax 149326 0
Email 149326 0
Contact person for public queries
Name 149327 0
Sophie Young
Address 149327 0
N372, Pharmacy and Bank Building A15 The University of Sydney, NSW, 2006
Country 149327 0
Australia
Phone 149327 0
+61 286275806
Fax 149327 0
Email 149327 0
Contact person for scientific queries
Name 149328 0
Sophie Young
Address 149328 0
N372, Pharmacy and Bank Building A15 The University of Sydney, NSW, 2006
Country 149328 0
Australia
Phone 149328 0
+61 286275806
Fax 149328 0
Email 149328 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.